<DOC>
	<DOCNO>NCT01427699</DOCNO>
	<brief_summary>The purpose study determine T2-18C3 , true human monoclonal antibody block inflammation , safe use patient type 2 diabetes . The study also look ability T2-18C3 improve control blood sugar level diabetic block inflammation pancreas .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics Anti-Inflammatory Therapeutic Antibody ( MABp1 ) Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This phase I , open label study safety pharmacokinetics T2-18C3 patient T2D . Nine patient receive four biweekly IV infusion study drug , T2-18C3 , dose level 1.25 mg/kg . These patient follow total 90 day examine safety , pharmacokinetics , preliminary efficacy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>American Diabetes Association ( ADA ) diagnostic criterion Type 2 Diabetes ( T2D ) HbA1c &gt; 7.0 % ≤ 10 % Current T2D duration &gt; 3 month Screening T2D disease must stable . Stable disease define disease require change medication dose level 4 consecutive day 7 day total within 28 day prior Day 0 . Age ≥ 18 ≤ 70 Screening BMI ≥ 23 ≤ 40 kg/m2 For female patient childbearing age , negative serum pregnancy test . For patient reproductive potential , willingness utilize adequate contraception ( oral contraception plus mechanical barrier ) become pregnant ( partner [ ] become pregnant ) study Agrees change diet exercise regimen trial Signed dated Ethics Committee ( EC ) approve informed consent protocolspecific screening procedure perform Use follow medication : Daily use steroid aspirin ≥ 700 mg per week Immunosuppressive treatment Thiazolidinediones Concomitant treatment therapeutic antibody , treatment biologic agent block IL1 TNFα signal pathway Change medication diabetes within 28 day prior Day 0 , define change dose level 4 consecutive day 7 day total Hemoglobin &lt; 10.0 g/dL , WBC &lt; 3.0 x 103/mm3 , platelet count &lt; 125 x 103/mm3 , creatinine &gt; 1.5mg/dL , AST/ALT &gt; 2 x ULN , alkaline phosphatase &gt; 2 x ULN Abnormal , untreated T3 , T4 , thyroglobulin , TSH level history Grave 's disease Known HIV antibody , hepatitis B surface antigen and/or hepatitis C antibody History malignancy within 5 year prior study entry carcinoma situ cervix , adequately treat , nonmetastatic squamous basal cell carcinoma skin History severe allergic anaphylactic reaction humanize murine monoclonal antibody History tuberculosis , positive PPD test , active atopic disease require medication , asthma Infectious disease : CRP &gt; 30 mg/L , fever , infection require treatment antibiotic within 3 week prior Screening History recurrent infection predisposition infection Active leg foot ulcer Immunodeficiency Female patient pregnant , plan become pregnant course study , breastfeed Receipt live ( attenuate ) vaccine within 3 month prior Screening Major surgery within 28 day prior Day 0 Participation investigational drug device trial within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>